Adrafinil is a synthetic wakefulness-promoting compound that is converted in the liver into modafinil. Developed in France and formerly marketed as Olmifon, it has been investigated for reduced alertness and cognitive symptoms. The page reviews research on wakefulness, fatigue, cognitive performance and its conversion to modafinil.
What Is Adrafinil?
Adrafinil is a synthetic wakefulness-promoting compound and prodrug of modafinil. After oral administration, the body converts adrafinil in the liver into modafinil, along with inactive or less active metabolites including modafinilic acid. Modafinil is therefore the principal pharmacologically active product associated with adrafinil. Because conversion must occur before substantial modafinil exposure is achieved, adrafinil generally has a slower, less predictable onset and a different pharmacokinetic profile from taking modafinil directly. It was investigated as a eugeroic, a term commonly used for agents intended to promote alertness without the broad stimulant profile of classical amphetamine-like drugs.
Adrafinil was developed in France in the 1970s by Lafon Laboratories and was subsequently marketed in France under the trade name Olmifon for indications related to reduced alertness and cognitive symptoms. Olmifon is no longer manufactured or marketed. In the United States, adrafinil is not scheduled under the federal Controlled Substances Act, but that fact does not make it an approved medicine, dietary supplement, or proven cognitive enhancer. Regulatory treatment varies by country, and products sold through online or research-chemical channels may not have reliable identity, purity, dose accuracy, or contamination controls. The absence of federal scheduling should not be interpreted as evidence of safety or legality for commercial sale, importation, or personal use.
Quick Reference
Member reference tables summarize the compound's research parameters.
Adrafinil is a prodrug converted in part to modafinil, a wakefulness-promoting agent studied in disorders involving excessive daytime sleepiness. Direct modern clinical evidence for adrafinil itself is limited.
Fatigue-related alertness
Research and historical use describe increased alertness and reduced subjective fatigue; effects can vary substantially with sleep debt, baseline fatigue, and conversion to modafinil.
Cognitive Performance
Preliminary Data
Attention during sleep loss
Evidence from the active metabolite, modafinil, suggests preservation of vigilance and some executive functions during sleep restriction. This should not be interpreted as replacing adequate sleep.
Executive-function tasks
Studies of modafinil in non-sleep-deprived participants report mixed, task-dependent effects on planning, attention, and decision-making; direct adrafinil trials are sparse.
Mood & Motivation
Emerging Evidence
Apathy and reduced drive
Older literature and anecdotal reports describe possible effects on initiative and psychomotor slowing, but robust contemporary controlled evidence is insufficient.
Subjective mood effects
Improved energy may be perceived as improved mood in some users, while anxiety, irritability, or insomnia may worsen mood in others.
Mechanistic Research
Preliminary Data
Prodrug conversion
After oral administration, adrafinil undergoes hepatic metabolism to modafinil and an inactive metabolite, making onset and exposure less predictable than direct modafinil administration.
Dopamine transporter activity
Modafinil has been shown to interact with dopamine transport processes, among other neurochemical systems; the complete basis of wakefulness promotion remains unresolved.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
A credible COA identifies the lot number, test date, testing laboratory, analytical method, and measured adrafinil content.
Verified Marker
Independent HPLC or LC-MS identity and purity testing
Prefer third-party chromatographic testing that reports identity confirmation and quantified purity rather than an unverified vendor claim.
Verified Marker
Heavy-metal and microbiological screening
Oral products should have current third-party results for lead, arsenic, cadmium, mercury, and relevant microbial contaminants.
Acceptable Range
Accurate capsule or tablet labeling
The declared milligrams per unit, excipients, serving size, and lot number should be clearly stated and consistent with the supporting assay.
Quality Concern
Missing, generic, or unverifiable laboratory documents
The listed research text specifies avoiding products with no lot-specific COA, implausibly perfect results, no laboratory traceability, or testing that does not identify the finished oral product.